This week, many of our Catalyst posts explored the value of medicinal development and its ability to improve the lives of patients. Although moving new drugs through the rigorous approval process is expensive and time consuming, several major triumphs for scientists and clinicians recently verified the value of investing in innovative research and development, citing the long-term human and economic benefits.
As I skim the new report “Medicines in Development for Older Americans,” I’m reminded how new medications that are still being developed and clinically tested have already begun to have positive impacts on patients and local economies all over the country.
Rx Response – an initiative by members of the pharmaceutical supply chain designed to keep medicines moving to patients in emergencies like a natural disasters – got some welcome recognition at the 2013 National Hurricane Conference in New Orleans this week. RxResponse Director and PhRMA Associate Vice Presi
A new cancer study is all over the news today, highlighting a batch of cancer “markers” that can help predict the disease earlier than before.
Today is the American Diabetes Association Alert Day, a one-day, "wake-up call" asking the American public to take the Diabetes Risk Test to find out if they are at risk for developing type 2 diabetes. One in three American adults - that's 79 million people- have pre-diabetes, which puts them at high risk for developing type 2 diabetes.
Dr. Curtis Triplett, an assistant professor of diabetes medicine at the University of Texas Health Science Center at San Antonio Texas Diabetes Institute, is a clinician on the front lines of the fight against diabetes.
Last week Senate Finance Committee Chair, Max Baucus (D. MT), and Ranking Member Orrin Hatch (R. UT) took a strong stand urging that the Administration secure robust intellectual property (IP) standards in the Trans-Pacific Partnership (TPP). In a letter to Ambassador Demetrios Marantis, Acting U.S.
The Supreme Court heard arguments today in the case of Federal Trade Commission v.
If we really want to "fix cancer," as Ezekiel Emanuel and a group of oncologists suggested in the New York Times this weekend, we should focus on how we can continue to build on medical innovation collaborations that can lead to better scientific knowledge and discovery of targeted treatments that can help defeat this complex dis
Recent reports by PhRMA on medicines in development for older Americans and on
03.22.13 | By Randy Burkholder
Pharmaphorum's interview with John Castellani is now live. Pharmaphorum interviewed Mr.
A new, experimental therapy for Leukemia is very promising, accordi
One of the most rewarding aspects of the "Research in Your Backyard" events that I've attended throughout the country is the chance to meet amazing people from all walks of life. One such person is Judy Orem, who I had the pleasure to get to know during an event in the Pacific Northwest last year.